메뉴 건너뛰기




Volumn 66, Issue SPEC. ISS., 2005, Pages 117-124

Liability issues in pharmacogenomics

Author keywords

[No Author keywords available]

Indexed keywords


EID: 33845868092     PISSN: 00246859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (7)

References (17)
  • 1
    • 77949932021 scopus 로고    scopus 로고
    • U. S. C. §§ 360aa-360ee (2004).
    • (2004) U. S. C. , vol.21
  • 2
    • 77949963258 scopus 로고    scopus 로고
    • Medical liability for pharmacogenomics, pharmacogenomics: Social
    • Mark A. Rothstein ed
    • Larry I. Palmer, Medical Liability for Pharmacogenomics, Pharmacogenomics: Social, Ethical, and Clinical Dimensions (Mark A. Rothstein ed., 2003).
    • (2003) Ethical, and Clinical Dimensions
    • Palmer, L.I.1
  • 6
    • 77950016228 scopus 로고    scopus 로고
    • supra note 3, at
    • Owen, supra note 3, at 564.
    • Owen1
  • 7
    • 77949948091 scopus 로고    scopus 로고
    • Id. at
    • Id. at 853.
  • 8
    • 77949966390 scopus 로고    scopus 로고
    • Epilogue: Policy prescriptions, pharmacogenomics: Social
    • Mark A. Rothstein ed
    • Mark A. Rothstein, Epilogue: Policy Prescriptions, Pharmacogenomics: Social, Ethical, and Clinical Dimensions 327 (Mark A. Rothstein ed., 2003).
    • (2003) Ethical, and Clinical Dimensions , pp. 327
    • Rothstein, M.A.1
  • 9
    • 77949979403 scopus 로고    scopus 로고
    • The gradual enfeeblement of the learned intermediary rule and the argument in favor of abandoning it entirely
    • James O. Castagnera et al., The Gradual Enfeeblement of the Learned Intermediary Rule and the Argument in Favor of Abandoning It Entirely, 36 Tort & Ins. L. J. 119 (2000-2001).
    • (2000) Tort & Ins. L. J. , vol.36 , pp. 119
    • Castagnera, J.O.1
  • 10
    • 0043104744 scopus 로고    scopus 로고
    • When drugs are safer for some but not others: The FDA experience and alternatives for products liability
    • Margaret Gilhooley, When Drugs Are Safer for Some But Not Others: The FDA Experience and Alternatives for Products Liability, 36 Hou. L. Rev. 927, 939 (1999).
    • (1999) Hou. L. Rev. , vol.36 , Issue.927 , pp. 939
    • Gilhooley, M.1
  • 11
    • 77949974337 scopus 로고    scopus 로고
    • Food and Drug Administration, Final Guidance on Direct-to-Consumer Advertising, Fed. Reg
    • Food and Drug Administration, Final Guidance on Direct-to-Consumer Advertising, 64 Fed. Reg. 43, 197 (1999).
    • (1999) , vol.64 , Issue.43 , pp. 197
  • 12
    • 77949923566 scopus 로고    scopus 로고
    • Food and Drug Administration, Report to Congress on Postmarketing Studies, available at
    • Food and Drug Administration, Report to Congress on Postmarketing Studies (2003), available at www.fda.gov/cber/fdama/pstmrktfdamal30.htm.
    • (2003)
  • 13
    • 0042855876 scopus 로고    scopus 로고
    • Ethical, legal and social implications of genetic medicine
    • Ellen Wright Clayton, Ethical, Legal and Social Implications of Genetic Medicine, 349 New Eng. J. Med. 562 (2003).
    • (2003) New Eng. J. Med. , vol.349 , pp. 562
    • Clayton, E.W.1
  • 14
    • 0031911191 scopus 로고    scopus 로고
    • ASHG Social Issues Subcommittee on Familial Disclosure, Professional Disclosure of Familial Genetic Information
    • ASHG Social Issues Subcommittee on Familial Disclosure, Professional Disclosure of Familial Genetic Information, 62 Am. J. Hum. Genet. 474 (1998).
    • (1998) Am. J. Hum. Genet. , vol.62 , pp. 474
  • 15
    • 77950007292 scopus 로고    scopus 로고
    • C. F. R. pts. 160
    • C. F. R. pts. 160, 164 (2005).
    • (2005) , vol.45 , pp. 164
  • 17
    • 77950018989 scopus 로고
    • Doctors debate use in tests of safer but costlier dyes
    • Dec. 2
    • Frank E. James, Doctors Debate Use in Tests of Safer but Costlier Dyes, Wall St. J., Dec. 2, 1988.
    • (1988) Wall St. J.
    • James, F.E.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.